Ribo’s bet on INHBE as an obesity target rests on something most early-stage programs lack: a human genetic proof of concept baked in before the first patient is dosed. The company has filed a Phase I Clinical Trial Application in the EU for RBD3133, an siRNA designed to silence INHBE, the gene encoding activin E. People who carry naturally occurring loss-of-function variants in that gene show healthier fat distribution and lower estimated risk of coronary heart disease and type 2 diabetes, and Ribo is now asking regulators to let it test whether artificially replicating that effect in adults with overweight or obesity produces the same picture.
The trial itself is randomized and placebo-controlled, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous RBD3133. The filing clears the path to a first-in-human readout, which will tell Ribo whether the drug reaches its target and moves the relevant metabolic markers before any dose-expansion decisions are made. The obesity therapeutics market is projected to reach $60.5 billion by 2030, growing at roughly 22% annually, so the commercial logic for a differentiated mechanism is straightforward enough. The harder question is whether INHBE silencing translates from genetics to pharmacology without the side-effect profile that plagues pathway-level metabolic interventions.
Ribo is not the only group pursuing this mechanism. Arrowhead Pharmaceuticals has been running its own RNAi candidate, ARO-INHBE, through a Phase 1/2a study and presented interim data at EASL 2026 showing clinically meaningful reductions in relevant endpoints, though those full results are not yet published in a peer-reviewed form. That puts Ribo in a race where the biology is validated but the clinical execution separates winners. RBD3133 is Ribo’s first obesity-area candidate, and this EU CTA comes through its Swedish subsidiary Ribocure, which suggests the company is building out clinical infrastructure in Europe rather than running the program solely from its China base. Wegovy’s approval in 2021 shifted physician and patient expectations for what weight loss medicines should achieve, and any new mechanism entering clinical development now inherits that efficacy bar.
The near-term signal to track is whether the EU clinical trial application clears without material objections, since the CTA review outcome will determine how quickly Ribo can dose its first cohort and generate the pharmacodynamic data that will define RBD3133’s path forward.
RBD3133: the facts in one place
- Also written: RBD3133 Injection
- Sponsor: Suzhou Ribo Life Science Co., Ltd. / Ribocure Pharmaceuticals AB
- Mechanism: siRNA targeting INHBE gene, silencing activin E expression
- Indication studied: overweight and obesity
- Phase: Phase I
- Primary endpoint: safety, tolerability, pharmacokinetics, and pharmacodynamics
- Registry identifier: not publicly listed
- Current status: Phase I Clinical Trial Application submitted in the EU; trial not yet commenced as of October 2026.
- EU Clinical Trial Application submission: October 8, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
